New Treatment Regime for Metastatic NSC Lung Cancer Patients

Professor Tony Mok, from The Chinese University of Hong Kong's Faculty of Medicine, in a joint study with international experts in lung cancer, discovered that combining the immune drugs tremelimumab and durvalumab with chemotherapy can significantly improve progression-free survival and overall survival of some lung cancer patients. Courtesy of CU Medicine

Lung cancer is the leading cancer killer and the most common type of cancer in Hong Kong. In a study, Professor Tony S.K. Mok of The Chinese University of Hong Kong’s (CUHK) Faculty of Medicine (CU Medicine) and  an international team of experts in lung cancer, found that combining the immunotherapy drugs tremelimumab and durvalumab with chemotherapy, can significantly improve progression-free survival and overall survival of patients with metastatic non-small cell lung cancer (NSCLC). This regimen represents a potential new option in first-line treatment for these patients.

The teams recruited 1,013 patients from 142 sites in 18 countries for a Phase 3 study that compared treatment outcomes of combined immunotherapy and chemotherapy versus chemotherapy alone.